Dr. Kevin Slater, Chief Executive Officer of the PetScreen, LTD Board ofDirectors, confirmed his company's participation by stating, "I am verypleased that our two companies have agreed to collaborate both commerciallyand technically to implement a range of new technologies aimed at improvingcancer diagnosis and treatment in companion animals. We believe that thiscollaboration will go a long way toward achieving our mutual goals,"concluded Slater.

PetScreen, LTD, formally incorporated in 2004 by Slater and board Chairman,Professor Graeme Radcliffe, was founded by people who have lost their petsto cancer and by experienced scientists who have worked on new methods forthe detection and treatment of cancer in companion animals. They use thelatest proven scientific developments to provide veterinarians withimproved testing methodologies to help them make better diagnostic andtreatment decisions for companion animals with cancer.

PetScreen, LTD is actively engaged in a comprehensive profile of services,combining testing, treatment and networking of national and internationalcollaborators to provide services and support to the veterinary cancerpatient. Gary Berthold, President and CEO of PharmaCom BioVet, Inc., addedhis enthusiasm for the agreement saying, "In forming this cooperativerelationship with PetScreen, LTD, we are continuing to broaden our linkswith cancer scientists and veterinary leaders on a world-wide basis; thusincreasing the opportunities for a greater range of research, diagnosis andtreatment technologies, and hastening the progress towards treatmentefficacy and an eventual cure of canine cancers."

After losing two of their prize Siberian Huskies to cancer, PharmaComBioVet, Inc. founders, Gary and Sharon Berthold, were inspired to searchfor meaningful remedies to this dreaded killer of companion canines. Intheir research, they discovered two alarming facts: 1) Statistically, onein three dogs is diagnosed with cancer at some time in their life, and atleast 50% of those dogs are likely to succumb. 2) Historically, there hasbeen an alarming lack of viable treatment options and facilities forcompanion animals suffering from cancer. Armed with this evidence andtheir own personal commitment, the Bertholds founded PharmaCom BioVet, Inc.to aggressively advance the establishment ofleading-edge, compassionate-care treatment centers using the latestscientific breakthroughs in cancer treatment.

Teaming up with international industry leaders such as PetScreen, LTD ofNottingham, UK and IsoTherapeutics Group, LLC of Angleton, Texas, PharmaComBioVet, Inc. is actively engaged in supporting global research, diagnosisand novel cancer treatment methodologies. "Our ultimate goal is toeradicate cancer in companion animals. To accomplish this great task, weare collaborating with the brightest minds in cancer research and oncologytreatment programs around the world," stated Berthold.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the veterinary careindustry for companion animals by establishing state-of-the-art treatmentcenters for lymphoma and other forms of cancer throughout the country. Thepurpose of these centers is to help prolong the quality of life forcompanion animals with cancer and pursue the potential for complete cure.These centers will also operate under the philosophy of providing acompassionate care environment for both companion animal patients and theirowners. For more information, please visit our websitewww.PharmaComBioVet.com.

About PetScreen, LTD:

PetScreen LTD. is headquartered and operates laboratories in Nottingham,England. Its purpose is to develop and apply new technologies directedtowards improving cancer diagnosis and treatment in dogs and othercompanion animals. Their facilities offer services such as Canine LymphomaBlood Tests which provide veterinarians with a simple means of screening,diagnosis and monitoring treatment of dogs with lymphoma. Their DCAprogram (Directed Chemotherapy Assay) helps in determining the mosteffective chemotherapy treatment for each individual canine cancer patient.From their UK location, they have developed a network of national andinternational collaborators to provide services and support to theveterinary cancer patient. For more information, please visit our websitewww.pet-screen.com.

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnosticand therapeutic agents for the treatment of severe diseases. ITG bothdevelops their own technologies as well as partners with other companies tohelp develop pharmaceuticals. Of special interest are radiopharmaceuticalsfor oncology. In house expertise includes synthetic organic chemistry,chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes,conjugation chemistry, pharmacokinetics, and small animal research models.For more information, please visit our website www.isotherapeutics.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Actof 1995: This press release contains forward-looking statements that aresubject to risk and uncertainties, including, but not limited to, theimpact of competitive products, product demand, market acceptance risks,fluctuations in operating results, political risk and other risks detailedfrom time to time in PharmaCom BioVet, Inc.'s filings with the Securitiesand Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'sactual results to differ materially from those expressed in anyforward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact:Market Ideas, Inc.877-295-3981 ext. 2info@marketideasinc.com